patients who begin with low and high levels and regardless of final level achieved. METHODS: A cohort of 27,660 patients with coronary artery disease, peripheral vascular disease, or diabetes mellitus were selected and followed retrospectively for their first myocardial infarction or revascularization recorded in the New England Veterans Affairs database. Pre-outcome low-density lipoprotein cholesterol reduction was categorized as follows: <10 mg/dl, reference; 10-39 mg/dl, small reduction; 40-69 mg/dl, moderate reduction; >70 mg/dl, large reduction. Cox proportional hazards was used to determine hazard ratios for each category of lipid reduction compared to reference and stratified by high or low initial LDL-C, adjusting for initial LDL-C, statin use, age, gender, and co morbidities. RESULTS: Among patients with initial LDL-C above the median of 133 mg/dL, hazard ratios (95% confidence intervals) for small, moderate, and large reductions compared to reference were 0.90 (0.85-0.96), 0.84 (0.79-0.90), and 0.76 (0.70-0.83) respectively. A total of 3448 or 24% of such patients achieved a final level <100 mg/dL. Among patients with initial levels below the median, hazard ratios (95% confidence intervals) for small, moderate, and large reductions were 0.90 (0.85-0.96), 0.87 (0.79-0.96), and 0.76 (0.56-1.05) respectively. A total of 5492 or 40% of such patients achieved final level <100 mg/dL. CON-CLUSION: These data suggest that magnitude of reduction in low-density lipoprotein cholesterol is proportional to degree of reduction in cardiovascular risk, and that this effect holds both for patients with initially low or high lipid levels, regardless of whether a final LDL-C of <100 mg/dL was achieved.
PCV14 ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN
Sicras A 1 , F Bobadilla J 2 , Moreno R 3 , Arístegui R 2 , García M 4 1 Badalona Servicios Asistenciales, Barcelona, Spain, 2 Pfizer Spain, Alcobendas, Madrid, Spain, 3 Hospital Clinico San Carlos, Madrid, Madrid, Spain, 4 Euroclin Institute, Alcobendas, Madrid, Spain OBJECTIVES: The lipid-lowering arm of ASCOT demonstrated that in hypertensive patients, in primary prevention who are not conventionally deemed dyslipidaemic and with at least three cardiovascular risk factors (CVRF), atorvastatin ten mg conferred a reduction in CV morbimortality. There are no data regarding the prevalence of these patients among the hypertensives in Spain. The objective is to determine the prevalence of the patient as defined in the ASCOT among the Spanish hypertensives. METHODS: Data from 2004 to 2005 of 6309 hypertensives from Spanish primary care centres were studied. We analyzed the following variables: left-ventricular hypertrophy, other specified abnormalities on EKG, type 2 diabetes, peripheral arterial disease, previous stroke, gender, age, microalbuminuria, smoking, ratio total cholesterol/HDL-cholesterol, and premature family history of CHD. We analyzed the Number of CVRF as defined in ASCOT and the percentage of patients with CVRF ≥3 (with normal TC and in primary prevention). RESULTS: Of the 6309 patients, 2528 (40%) had history of CHD and/or heart failure and/or TC >250 mg/dl and/or a statin treatment. The presence of ASCOT-CVFR ≥3 was analyzed in the 3781 remaining ones. The percentage of additional CVRF relative to these 3781 patients was: 0 FRCV: 4.3%; 1 FRCV: 24.6%; 2 FRCV: 30.4%; 3 FRCV: 22.2%; 4 FRCV: 11.8%; 5FRCV: 5.1%; 6 FRCV: 1.3%; 7 FRCV: 0.3%; 8 FRCV: 0.03%. There were 1540 patients (40.7%) with CVRF ≥3. This percentage, in relation to the whole population of hypertensives (6309) was 24.4%. CON-CLUSIONS: Because of the retrospective nature of the design, it is advisable to be prudent in the external generalization. Nevertheless a high prevalence (at least 40.7%) of the ASCOT-patient (CVRF ≥3), relative to a population of Spanish hypertensive patients in primary prevention, not treated with statins and with total cholesterol ≤250 mg/dL, have been demonstrated.
PCV15

ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)
The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2 Thomas Jefferson University, Philadelphia, PA, USA OBJECTIVE: The ALLHAT study, published in December of 2002, indicated improved outcomes for hypertensive patients on thiazide diuretics. This study evaluated the utilization of thiazides in hypertensives in the year before and after the publication of these results in a national primary care database. METHODS: A retrospective review of an electronic medical record (EMR) database (GE Medical Systems Centricity) containing the ambulatory health record data for over 3.2 million individuals was conducted. Patients with an ICD-9 code for hypertension (HPTN) and a GPI code for thiazide diuretic were identified in calendar years 2002 and 2003. Patients in each year on thiazides, on or after HPTN diagnosis, were taken as a percentage of those with hypertension. RESULTS: In the year 2002 there were 81,916 patients with hypertension, 40,392 patients on thiazide diuretics and 17,520 patients with both. Of those, 15,253 had their thiazide prescription on or after the date of HPTN diagnosis. In 2003 there were 114,347 patients with HPTN, 56,796 on thiazides, 26,199 with HPTN and 22,321 with their thiazide prescription on or after HPTN diagnosis. The percent of hypertensives on thiazides was 18.62% in 2002 and 19.52% in 2003 with an increase of 0.9% in thiazide use in patients with hypertension. CONCLUSION: Despite published evidence of improved outcomes for hypertensive patients treated with thiazide diuretics, the increase utilization in a primary care database was modest.
PCV16 MAIN CARDIOVASCULAR RISK FACTORS: ASSOCIATION AND CONTROL IN A PRIMARY HEALTH CARE SETTING
Sicras A 1 , Navarro R 1 , Rejas J 2 , F Bobadilla J 2 , García M 3 , González P 2 1 Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2 Pfizer Spain, Alcobendas, Madrid, Spain, 3 Euroclin Institute, Alcobendas, Madrid, Spain OBJECTIVES: To determine the association and The rapeutic control goals of certain cardiovascular risk factors (CVRF) in a Spanish primary care population. METHODS: A retrospective study was performed based on patient's data from five ambulatory primary care centres. Patients aged >18 years, attended during year 2004, with at least one major CVRF were included. The following variables were analysed: age, sex, main diagnosis (hypertension, dyslipidemia, diabetes and/or cardiovascular event [ECV]) and clinical parameters (systolic blood pressure, diastolic blood pressure, LDLc, HbA1c). Therapeutic control goals were established according to NCEP-ATP III. A bivariant analysis and a binary logistic regression model were performed to fit the model. The statistical program SPSS was used with a 5% significance level. RESULTS: A total of 15,470 patients had at least one CVRF. Mean age was 61.3 ± 14.3; 53.7% were female and 14.2% had a history of CVD. The diagnosis was hypertension in 60.6%, diabetes in 26.7% and hipercolesterolemia in 49.5%. The presence of CVRF >3 was confirmed in 5.8% and CVD in 28.3%. The percentage of patients who uncontroled BP or TC was 46.4% and 48.7%, respectively. The correction of the logistic model demonstrated the association of CVD with male sex (OR = 2.6), diabetes (OR = 2.2), dyslipidemia (OR = 1.6), BP (OR = 1.3) and age (OR = 1.1), p < 0.05. CONCLUSIONS: Therapeutic control goals in primary care setting might be improved. It would be necessary to make new representative studies showing the degree of control of our patients in daily clinical practice.
PCV17 PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN ® ) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES
Liens D 1 , Palmer AJ 2 ,Valentine WJ 2 , Renaudin C 1 , Roze S 2 1 Merck Santé, Lyon, France, 2 CORE-Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland OBJECTIVES: A recent Pan-European Survey highlighted a prevalence of low High Density Lipoprotein-cholesterol (HDL-c <1.03 mmol/L in men and <1.29 mmol/l in women) in over 30% of patients diagnosed with dyslipidemia, irrespective of statin treatment. In order to help physicians focus their attention on this risk factor, a model was used to project clinical benefits on coronary heart disease (CHD) endpoints of raising HDL-c by adding Niaspan ® to statin therapy in Type 2 Diabetes (T2D) patients. METHODS: A computer model simulated the clinical benefit of combination therapy statin + Niaspan ® ; the first submodel (Monte-Carlo simulation) generated a cohort using patient characteristics from the Pan-European Survey (diabetic sub-group) and applied Niaspan ® treatment effect (European SPC, 2 g/day); the second sub-model (Markov) estimated the long-term clinical outcomes associated with patient's lipid changes (Framingham risk equations). Simulations were run to capture 5, 10 years and patients' lifetimes. RESULTS: In these patients, mean life expectancies of 19.42 years and 18.78 years were projected for the statin + Niaspan ® and statin monotherapy arms respectively (difference of 0.64 years). The addition of Niaspan ® to statin treatment was associated with a lower cumulative incidence of CHD events than statin monotherapy at different time horizons leading to absolute risk reductions of 14.1% for myocardial infarction and 5.5% for CHD death. CON-CLUSIONS: Due to its positive effect on HDL-c levels, the addition of Niaspan ® to statin treatment was projected to reduce the cumulative incidence of CHD events compared to statin monotherapy in a European T2D patient population with persistently low HDL-c.
PCV18
OUTCOME OF THIAZOLIDINEDIONE USE IN DISCHARGED DIABETIC PATIENTS WHO WERE HOSPITALIZED FOR HEART FAILURE
Chou HY 1 , Huang WF 2 , Tsai YW 3 1 National Yang-Ming University, Taipei City, Taiwan, 2 National Yang-Ming University, Taipei, Taiwan, 3 National Health Research Institutes, Zhunan Town, Taiwan OBJECTIVES: Thiazolidinedione (TZD) was recommended not for patients with moderate and serious heart failures due to the adverse reaction of body fluid retention. Our study investigated the use of TZD by type 2 diabetic patients after they were discharged from hospitalizations for heart failure. METHODS: The cohort observation was based on claims database of Taiwan's National Health Insurance (NHI) for 2002∼2004. There were 4774 diabetic patients who were hospitalized due to heart failure during 2003: 379 TZD users and 4395 non-TZD users. A total of 2692 non-TZD users who used sulfonylurea after discharge were selected as the control group. Cox proportional hazard models were estimated to compared the outcomes of death and readmission to hospitals of TZD users and sulfonylurea users, one year after the time patients were discharged. RESULTS: There were 7.9% of diabetic patients who were hospitalized for heart failure and received TZD treatments. There was no significant difference on readmission over one year after discharge between the two groups. However, among those who used TZD or sulfonylurea less than 60 days, those who used TZD had lower HR of readmission than those who used sulfonylurea (HR 0.728, 95% CI 0.551∼0.962). Overall, the HR for death among patients receiving TZD was significant lower than the control group of sulfonylurea users (HR 0.092, 95% CI = 0.022-0.380). CONCLUSIONS: Based on the precautions stated in TZD package inserts, 7.9% of type 2 diabetic patients with heart failure received potentially inappropriate prescriptions. Short term use of TZD significantly reduced hazards ratio in readmission, though long term use of both TZD and sulfonylurea showed no difference on readmission, and the use of TZD significantly reduced the hazard of death.
PCV19 DISCONTINUED USE OF MYCOPHENOLATE MOFETIL AND GRAFT LOSS IN HEART TRANSPLANT RECIPIENTS
Legorreta AP 1 , Kang N 2 , Gilmore AS 2 , Marehbian J 2 , Naujoks C 3 , Machnicki G 3 1 UCLA School of Public Health, Los Angeles, CA, USA, 2 Health Benchmarks, Inc, Woodland Hills, CA, USA, 3 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: Changing patterns of immunosuppression use have been associated with increased risk of adverse graft and patient survival outcomes. This study aimed to assess the relationship between discontinuing use of mycophenolate mofetil (MMF) on two-year graft loss and two-year patient death. METHODS: US claims data from commercial health plans for 396 patients receiving heart transplants (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) were linked to data from the Organ Procurement Transplant Network (OPTN). Transplant recipients were grouped into two: those who continued and those who discontinued (MMF DC) using MMF. MMF use was defined as having ≥1 pharmacy claim posttransplant for the medication. Discontinuation was defined as more than a 30 day gap in MMF coverage followed by no subsequent refills during the year following the initial MMF script. Cox proportional hazards analysis was used to estimate the risk of discontinuing MMF on graft loss and dying. RESULTS: Thirteen percent (N = 52) of the study population was in the MMF DC group. The majority of the population was between age 41 and 60 (57%), male (78%), transplanted between 1996-2000 (44%), and received a medication for a gastrointestinal condition during the year following their initial MMF script (65%). Discontinuing use of MMF was associated with an increased risk of graft loss (Hazard Ratio [HR] = 3.45 p = 0.04) and an increased risk of death (HR = 2.79, p = 0.01) compared to continued MMF use during the year of follow-up. CONCLUSIONS: Disrupting the pattern of MMF use was related to a significant increase in the risk of graft loss and death during two years post transplant in this heart transplant recipient population covered by commercial health plans. Future work should examine whether these findings extend to heart transplant recipients covered by other types of insurance and potential causes of therapy discontinuation.
